WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015035941) USE OF ANNEXIN A3 AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER AND THERAPEUTIC TARGET FOR TREATING HEPATOCELLULAR CARCINOMA
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/035941    International Application No.:    PCT/CN2014/086416
Publication Date: 19.03.2015 International Filing Date: 12.09.2014
Chapter 2 Demand Filed:    07.07.2015    
IPC:
A61K 48/00 (2006.01), A61P 35/00 (2006.01), G01N 33/574 (2006.01)
Applicants: VERSITECH LIMITED [CN/CN]; Room 405A, Cyberport 4 100 Cyberport Road Hong Kong (CN)
Inventors: MA, Kwai Yee, Stephanie; (CN).
TONG, Man; (CN).
GUAN, Xinyuan; (CN)
Agent: CHINA PATENT AGENT (H.K.) LTD.; 22/F., Great Eagle Center 23 Harbour Road, Wanchai Hong Kong (CN)
Priority Data:
61/877,061 12.09.2013 US
Title (EN) USE OF ANNEXIN A3 AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER AND THERAPEUTIC TARGET FOR TREATING HEPATOCELLULAR CARCINOMA
(FR) UTILISATION DE L'ANNEXINE A3 EN TANT QUE BIOMARQUEUR DE DIAGNOSTIC ET DE PRONOSTIC ET CIBLE THÉRAPEUTIQUE POUR LE TRAITEMENT D'UN CARCINOME HÉPATOCELLULAIRE
Abstract: front page image
(EN)Annexin A3 (ANAX3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (HCC) and the utilization of a monoclonal antibody against ANXA3 or antisense polynucleotide against ANXA3 mRNA for the suppression or treatment of HCC, alone or in combination with other HCC treatment. Monoclonal antibody against ANXA3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance.
(FR)La présente invention concerne l'utilisation d'annexine A3 (ANXA3) en tant que biomarqueur pour le diagnostic et le pronostic du carcinome hépatocellulaire (HCC) et l'utilisation d'un anticorps monoclonal contre l'ANXA3 ou d'un polynucléotide antisens contre l'ARNm d'ANXA3 pour la suppression ou le traitement d'un HCC, seul ou en combinaison avec d'autres composants contre le HCC. L'anticorps monoclonal contre l'ANXA3 peut être administré pour la suppression de la croissance tumorale, de la métastase, et de la chimiorésistance.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)